Xiling Shen

Adjunct Professor in the Department of Pathology

Dr. Shen’s research interests lie at precision medicine and systems biology. His lab integrates engineering, computational and biological techniques to study cancer, stem cells, microbiota and the nervous system in the gut. This multidisciplinary work has been instrumental in initiating several translational clinical trials in precision therapy. He is the director of the Woo Center for Big Data and Precision Health (DAP) and a core member of the Center for Genomics and Computational Biology (GCB).

Appointments and Affiliations

• Adjunct Professor in the Department of Pathology

Contact Information

• Office Location: 2167 Ciemas, 101 Science Drive, Box 3382, Durham, NC 27708
• Office Phone: (919) 681-9184
• Email Address: xiling.shen@duke.edu
• Websites:
  • Woo Center for Big Data and Precision Health
  • Xiling Shen's lab page

Education

• Ph.D. Stanford University, 2008
• M.Sc. Stanford University, 2001
• B.Sc. Stanford University, 2001

Research Interests

Precision medicine for cancer, regeneration, microbiome, and gut-brain axis. Multi-omics approaches including organoid, epigenetics, CRISPR, single-cell, metabolomics, machine learning, droplet microfluidics, humanized immune model and intravital imaging.

Courses Taught

• BME 590: Special Topics in Biomedical Engineering
• BME 791: Graduate Independent Study
• BME 792: Continuation of Graduate Independent Study

In the News

• The Cancer Microbiome Reveals Which Bacteria Live in Tumors (Jan 13, 2021 | Pratt School of Engineering)
• A Rare Window Into the Workings of the Colon in a Live Animal (Dec 11, 2019 | Pratt School of Engineering)
• Cancer Cells Adapt to Gorge on Sugar in the Liver (Apr 27, 2018 | Pratt School of Engineering)
• Cancer Drug Helps Treat Tuberculosis (Apr 27, 2018)
• A literal window into the second brain in our stomachs (Jun 23, 2016 | Newsweek)
• A literal window into the second brain in our stomachs (Jun 13, 2016 | Newsweek)
• Window in mouse shows its ‘gut feelings’ (Jun 8, 2016 | Gizmag)
• Window in mouse shows its ‘gut feelings’ (Jun 8, 2016 | Gizmag)
• Real-time View of Enteric Nervous System Provides a Window to the Gut's Brain (Jun 7, 2016)
• How Gut Inflammation Sparks Colon Cancer (Feb 4, 2016)
• Xiling Shen: An Engineering Approach to Biomedical Challenges (Feb 24, 2015 | Pratt School of Engineering)

Representative Publications

• Giroux, NS; Ding, S; McClain, MT; Burke, TW; Petzold, E; Chung, HA; Rivera, GO; Wang, E; Xi, R; Bose, S; Rotstein, T; Nicholson, BP; Chen, T; Henao, R; Sempowski, GD; Denny, TN; De Ussel, MI; Satterwhite, LL; Ko, ER; Ginsburg, GS; Kraft, BD; Tsalik, EL; Shen, X; Woods, CW, Author Correction: Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion., Scientific Reports, vol 13 no. 1 (2023) [10.1038/s41598-023-33323-8] [abs].
• Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS, Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer (2023) [10.1158/1535-7163.22521145] [abs].
• Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS, Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer (2023) [10.1158/1535-7163.22521148] [abs].
• Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS, Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer (2023) [10.1158/1535-7163.22521148.v1] [abs].
• Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS, Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer (2023) [10.1158/1535-7163.22521145.v1] [abs].